Chikungunya virus (CHIKV) is a mosquito-borne alphavirus causing fever, severe joint pain, rash, and muscle aches, mainly transmitted by Aedes mosquitoes. The outbreak began on islands in the Indian Ocean and had spread to 119 countries by 2025, including temperate regions such as France. Key control strategies include vector control, surveillance, health system preparedness, and international cooperation. Sino Biological supports research by providing recombinant CHIKV antigens and antibodies, which are useful for vaccines, antiviral drugs, and diagnostics.
Alzheimer’s antibody Lecanemab launched in the EU
Latest NewsSwedish BioArctic AB’s partner Eisai Pharma has started the European roll-out of their Alzheimer’s antibody lecanemab in Austria that will be followed by the German launch on September 1, 2025.
About POWTECH TECHNOPHARM
slider, Sponsored Publications, VideosPOWTECH TECHNOPHARM (Nuremberg, 23-25 September 2025) is the international trade fair for process engineering experts and a tailor-made technology platform for the pharmaceutical and life science industries.
US and EU confirm tariff deal on pharmaceuticals, generics largely exempt
Latest NewsThe US and EU have confirmed a trade agreement involving US import tariffs of 15% on prescription medicines. Generics manufacturers will face a maximum tariff of 2.5%.
New Head of Development
AppointmentsSwedish AlzeCure Pharma AB recently appointed Cecilia Wadell as Head of Development. She joins also the management team.
Mallia Aesthetics is about to launch MAL-838
Latest NewsGermany’s Mallia Aesthetics GmbH has announced the achievement of key regulatory milestones in preparation for the market launch of its sCD83-based hair growth stimulant, MAL-838, later this year.
2025 Chikungunya Outbreak: A Global Health Challenge
Sponsored PublicationsChikungunya virus (CHIKV) is a mosquito-borne alphavirus causing fever, severe joint pain, rash, and muscle aches, mainly transmitted by Aedes mosquitoes. The outbreak began on islands in the Indian Ocean and had spread to 119 countries by 2025, including temperate regions such as France. Key control strategies include vector control, surveillance, health system preparedness, and international cooperation. Sino Biological supports research by providing recombinant CHIKV antigens and antibodies, which are useful for vaccines, antiviral drugs, and diagnostics.
BioMed X and Novo Nordisk collaborate to optimise oral peptide therapeutics
Latest NewsNovo Nordisk has entered a collaboration with research institute BioMed X in an effort to regain market position lost to leading competitors in diabetes and obesity treatment. The partnership is focused on improving the low bioavailability of orally administered peptide-based medicines.
Anocca raises €38.4m to advance TCR-T leads vs. pancreatic cancer
Latest NewsSwedish immunoncology specialist Anocca AB has raised SEK440m (€38.36m) ahead of enrolling pancreatic cancer patients in a Phase I umbrella trial evaluating the safety of its T-cell receptor-engineered T cell (TCR-T) programmes ANOC-001, ANOC-002 and ANOC-003.
Merck and mantro enter the foodtech market
Latest NewsThe laboratory division of Merck KGaA has, in partnership with the German company builder Mantro GmbH, established EdiMembre Inc, a Massachusetts-based company set to deploy Merck’s technologies for the production of structured meat alternatives – primarily Merck’s edible membranes.
Successor found for CEO
AppointmentsSana Alajmovic has been appointed as the new CEO of the Swedish company Enzymatica AB by the Board of Directors. The current CEO, Claus Egstrand, will become a member of the Board.